{
  "openalex_id": "W2253920138",
  "doi": "https://doi.org/10.1200/jco.1988.6.9.1377",
  "title": "A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.",
  "abstract": "This study was designed to assess the role of dosage of chemotherapy for treatment of metastatic breast cancer. One hundred thirty-three patients without prior chemotherapy for metastatic disease were randomly allocated to receive two different dose levels of cyclophosphamide (C), methotrexate (M), and fluorouracil (F), administered intravenously (IV) every 3 weeks. Patients were stratified by sites of disease (visceral, bone, or soft-tissue dominant) and by interval from primary surgery to first recurrence. Doses on the higher-dose arm were 600 mg/m2 (C,F) and 40 mg/m2 (M) with escalation if possible; doses on the lower-dose arm were 300 mg/m2 (C,F) and 20 mg/m2 (M) without escalation. Patients who failed to respond to lower-dose CMF were crossed over to the higher-dose arm. Patients randomized to the higher-dose arm had longer survival measured from initiation of chemotherapy (median survival, 15.6 months v 12.8 months, P = .026 by log-rank test), but the effect of dose was of borderline significance (P approximately 0.12) when adjusted for a chance imbalance between the two arms in the time from first relapse to randomization, using the Cox proportional hazards model. Response rates (International Union Against Cancer [UICC] criteria) for patients with measurable disease were higher-dose arm: 16/53 (30%) and lower-dose arm: 6/53 (11%), (P = .03). Only one of 37 patients responded on crossover from the lower- to the higher-dose arm. Patients experienced more vomiting, myelosuppression, conjunctivitis, and alopecia when receiving higher doses of chemotherapy. A series of 34 linear analogue self-assessment scales were used to make detailed quality of life assessments on a subset of 49 patients. These scales confirmed greater toxicity in the immediate posttreatment period, but also a trend to improvement in general health and some disease-related indices, in patients receiving higher-dose chemotherapy. This trial suggests that better palliation is achieved by using full-dose chemotherapy.",
  "authors": [
    {
      "display_name": "Ian F. Tannock",
      "id": "A5063846121",
      "orcid": "https://orcid.org/0000-0002-2636-7041",
      "institutions": [
        {
          "id": "I2802654988",
          "display_name": "Princess Margaret Cancer Centre",
          "country_code": "CA",
          "type": "healthcare"
        },
        {
          "id": "I185261750",
          "display_name": "University of Toronto",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "I F Tannock"
    },
    {
      "display_name": "N F Boyd",
      "id": "A5112151862",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "N F Boyd"
    },
    {
      "display_name": "George Deboer",
      "id": "A5110877351",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "G DeBoer"
    },
    {
      "display_name": "Charles Erlichman",
      "id": "A5022511085",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "C Erlichman"
    },
    {
      "display_name": "Shai Fine",
      "id": "A5040827183",
      "orcid": "https://orcid.org/0000-0002-9346-8774",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "S Fine"
    },
    {
      "display_name": "Gail Larocque",
      "id": "A5054245141",
      "orcid": "https://orcid.org/0000-0001-9979-6659",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "G Larocque"
    },
    {
      "display_name": "Catherine Mayers",
      "id": "A5040377827",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "C Mayers"
    },
    {
      "display_name": "D Perrault",
      "id": "A5110037843",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "D Perrault"
    },
    {
      "display_name": "Heather Sutherland",
      "id": "A5017785108",
      "orcid": "https://orcid.org/0000-0003-3126-4749",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "H Sutherland"
    }
  ],
  "publication_year": 1988,
  "publication_date": "1988-09-01",
  "type": "article",
  "cited_by_count": 355,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S15137598",
    "display_name": "Journal of Clinical Oncology",
    "issn_l": "0732-183X",
    "issn": [
      "0732-183X",
      "1527-7755"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310315671"
  },
  "volume": "6",
  "issue": "9",
  "first_page": "1377",
  "last_page": "1387",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.9337836
    },
    {
      "id": "C2776755627",
      "display_name": "Cyclophosphamide",
      "level": 3,
      "score": 0.742423
    },
    {
      "id": "C2776694085",
      "display_name": "Chemotherapy",
      "level": 2,
      "score": 0.66792905
    },
    {
      "id": "C530470458",
      "display_name": "Breast cancer",
      "level": 3,
      "score": 0.5775756
    },
    {
      "id": "C2780456651",
      "display_name": "Fluorouracil",
      "level": 3,
      "score": 0.54234755
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.5406347
    },
    {
      "id": "C2775930923",
      "display_name": "Metastatic breast cancer",
      "level": 4,
      "score": 0.5394154
    },
    {
      "id": "C204243189",
      "display_name": "Randomization",
      "level": 3,
      "score": 0.5207793
    },
    {
      "id": "C2781059491",
      "display_name": "Methotrexate",
      "level": 2,
      "score": 0.5041436
    },
    {
      "id": "C2780852908",
      "display_name": "Vomiting",
      "level": 2,
      "score": 0.4904823
    },
    {
      "id": "C2777909004",
      "display_name": "Capecitabine",
      "level": 4,
      "score": 0.48841375
    },
    {
      "id": "C141071460",
      "display_name": "Surgery",
      "level": 1,
      "score": 0.46601182
    },
    {
      "id": "C90924648",
      "display_name": "Gastroenterology",
      "level": 1,
      "score": 0.43533927
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.40750125
    },
    {
      "id": "C168563851",
      "display_name": "Randomized controlled trial",
      "level": 2,
      "score": 0.348205
    },
    {
      "id": "C526805850",
      "display_name": "Colorectal cancer",
      "level": 3,
      "score": 0.07124528
    }
  ],
  "topics": [
    {
      "id": "T11752",
      "display_name": "Cancer Treatment and Pharmacology",
      "score": 0.9998
    },
    {
      "id": "T10178",
      "display_name": "Cancer survivorship and care",
      "score": 0.999
    },
    {
      "id": "T12937",
      "display_name": "Chemotherapy-related skin toxicity",
      "score": 0.9971
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1200/jco.1988.6.9.1377",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:46:35.259794",
  "source_database": "OpenAlex"
}